Novel patent publications on high-affinity nicotinic acid receptor agonists. - Wikidata - awgldk - TriplyDB

Novel patent publications on high-affinity nicotinic acid receptor agonists.

Novel patent publications on high-affinity nicotinic acid receptor agonists.

http://www.wikidata.org/entity/Q37529810

about

Niacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part II: Novel Niacin Mimetics GPR109A and vascular inflammation Future of GPR109A agonists in the treatment of dyslipidaemia.Niacin: the evidence, clinical use, and future directions.Effects of nicotinic acid on gene expression: potential mechanisms and implications for wanted and unwanted effects of the lipid-lowering drug.Cell-surface G-protein-coupled receptors for tumor-associated metabolites: A direct link to mitochondrial dysfunction in cancer.Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia.

P2860

Q26765137-CF417627-AFC8-41DC-A48E-E44084289849 Q28287747-D2114B3C-91AB-412E-BC9B-BDB8226A5866 Q34171831-75E178BA-0634-4D2A-8C39-2F99FC7389F8 Q34228636-1B0C267F-AFD7-447C-991E-5FFAC72CC96C Q35432791-BE6CFDC0-9467-4E7C-A22D-ED774E41B1AA Q39312047-25749B9C-0807-42A1-A90F-50151365D1A6 Q39735403-E2B06F64-BF08-4FC4-9F09-CBFE32852375

P2860

Novel patent publications on high-affinity nicotinic acid receptor agonists.

http://www.wikidata.org/entity/Q37529810

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on July 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Novel patent publications on high-affinity nicotinic acid receptor agonists.

@en

Novel patent publications on high-affinity nicotinic acid receptor agonists.

@nl

type

label

Novel patent publications on high-affinity nicotinic acid receptor agonists.

@en

Novel patent publications on high-affinity nicotinic acid receptor agonists.

@nl

prefLabel

Novel patent publications on high-affinity nicotinic acid receptor agonists.

@en

Novel patent publications on high-affinity nicotinic acid receptor agonists.

@nl

P1433

Q37529810-F74C5E1C-8248-4D52-83F7-A338BC682C34

P1476

Q37529810-2FC74286-C422-458D-A1F1-EEDAB50812C3

P2093

Q37529810-085EEE87-4847-4843-ABEA-E8E908FE3B9F

Q37529810-1AA3E24A-EC3A-4DF4-B424-10E7E2148DC4

P2860

Q37529810-158008ED-3A86-4634-A5B7-1FC66DCBCB3F

Q37529810-168BCA95-584F-4008-8784-18FDF0A1FED2

Q37529810-22E58A8C-7224-4481-BA62-72EC8360DF2D

Q37529810-27A592B0-1C62-4B1E-896D-9076F612E96D

Q37529810-2CC459CD-8C8B-472D-834A-B8E1A55640B1

Q37529810-32BADEC9-16C2-4984-A59D-BAC6B212E5AB

Q37529810-3709EC2E-E5A5-4A70-ADBB-AB099F857095

Q37529810-389EC936-0B41-4786-A6F6-2F0FBFFE9055

Q37529810-405E1A5D-6CD9-415F-80CE-9CDF22F657BF

Q37529810-4A38C579-6B0B-4A73-88CD-FBB483D65E30

P304

Q37529810-632E0DEA-D1F3-4F41-B9D9-2E6674BB4A05

P31

Q37529810-DBD30623-197D-4163-91C8-92184444E9FA

P356

Q37529810-4FCB99D4-A69A-45EC-BCF5-5F733241E2F2

P407

Q37529810-2343ED52-6FE1-457D-90CA-AF26828EF3A2

P433

Q37529810-94506136-8813-4EB4-A546-BE98434650AD

P478

Q37529810-BB86FF5B-DB60-4676-9124-5AA8F90245C0

P577

Q37529810-9698FC2E-91C6-4FD6-93FC-350986006F18

P698

Q37529810-3CE193B4-8948-42A0-8A65-C8C94DB30571

P356

13543770902991526

P1433

Expert Opinion on Therapeutic Patents

P1476

Novel patent publications on high-affinity nicotinic acid receptor agonists.

@en

P2093

Hong C Shen

http://www.w3.org/2001/XMLSchema#string

Steven L Colletti

http://www.w3.org/2001/XMLSchema#string

P2860

GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing

Molecular identification of high and low affinity receptors for nicotinic acid

PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect

Drug treatment of lipid disorders.

Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century.

Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans.

A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients.

New lipid-modifying therapies.

HDL: the metabolism, function, and therapeutic importance.

Bioisosterism: a useful strategy for molecular modification and drug design.

P304

957-967

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543770902991526

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P577

2009-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19552512

http://www.w3.org/2001/XMLSchema#string